FY2028 EPS Forecast for COMPASS Pathways Lowered by Analyst

COMPASS Pathways plc (NASDAQ:CMPS) – Research analysts at HC Wainwright decreased their FY2028 EPS estimates for COMPASS Pathways in a research note issued on Thursday, February 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.14 for the year, down from their previous estimate of $0.24. HC Wainwright currently has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ FY2029 earnings at $1.63 EPS.

Several other research analysts have also recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways has a consensus rating of “Buy” and a consensus target price of $30.60.

COMPASS Pathways Price Performance

CMPS opened at $4.42 on Friday. The stock’s 50 day moving average price is $4.10 and its 200 day moving average price is $5.49. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPS. Altium Capital Management LLC acquired a new stake in COMPASS Pathways in the 4th quarter valued at about $5,384,000. Marshall Wace LLP acquired a new stake in COMPASS Pathways during the fourth quarter valued at approximately $1,395,000. PEAK6 LLC bought a new stake in COMPASS Pathways during the fourth quarter worth approximately $186,000. Affinity Asset Advisors LLC grew its position in COMPASS Pathways by 183.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company’s stock worth $3,215,000 after buying an additional 550,000 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company’s stock valued at $1,585,000 after buying an additional 8,718 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.